Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Broad Applications of its CTP Platform for Long Acting



PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Broad
    Applications of its CTP Platform for Long Acting Therapeutic Proteins

PR Newswire

NES-ZIONA, Israel, Jan. 7, 2013

NES-ZIONA, Israel, Jan. 7, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE
MKT: PBTH) today announced that it received a notice of allowance from the
U.S. Patent and Trademark Office for a patent application covering the
company's CTP platform, which has the potential to extend the duration of
activity of therapeutic proteins.  The allowed claims cover manufacturing
methods for CTP-modified compositions of a wide array of classes of
therapeutic proteins, including hormones, high affinity protein ligands,
proteins that induce or regulate an immune response, proteins involved with
autocrine and paracrine activities, and mimetics of these therapeutic
proteins, as well as other types of proteins.

This new U.S. patent is expected to be issued in the next few months.  

"Upon issuance, this new patent is expected to further strengthen PROLOR's
expanding intellectual property portfolio covering the CTP platform, as well
as the new products we are developing using this versatile technology," said
Shai Novik, president of PROLOR. 

About PROLOR's CTP Technology

PROLOR's CTP technology is based on the naturally-occurring human carboxyl
terminal peptide (CTP).  When attached to a therapeutic protein, CTP
significantly extends the length of time the protein remains active in the
body.  Clinical and preclinical studies have shown that the CTP technology
appears to be safe and effective in extending the duration of all proteins
tested to date.  CTP's safety and efficacy have also been validated by the
marketing approval of Merck's long-acting CTP-enhanced fertility drug Elonva^®
(FSH-CTP).  A single Elonva injection replaces a regimen of seven daily FSH
injections.  Results from a Phase II trial of PROLOR's CTP-modified human
growth hormone (hGH-CTP) in growth hormone deficient adults showed that a
single weekly injection of hGH-CTP has the potential to replace seven
consecutive daily injections of currently marketed human growth hormone.  CTP
was identified by researchers at Washington University in St. Louis and is
exclusively licensed to PROLOR for all proteins and peptides, except for four
endocrine proteins that are licensed to Merck.  CTP is manufactured using
standard industrial biotech processes.

ABOUT PROLOR

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology, primarily to develop
longer-acting proprietary versions of already approved therapeutic proteins
that currently generate billions of dollars in annual global sales.  The CTP
technology is applicable to virtually all proteins.  PROLOR is currently
developing a long-acting version of human growth hormone, which successfully
completed a Phase II clinical trial.  It also is developing long-acting
versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual
receptor agonist peptide for diabetes and obesity, all of which are in
preclinical development.  For more information, visit
http://www.prolor-biotech.com.

Safe Harbor Statement:  This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.  Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties.  In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission.  The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

PROLOR CONTACT:                            MEDIA CONTACT:
Shai Novik, President                      Barbara Lindheim
PROLOR Biotech, Inc.                       BLL Partners, LLC
Tel: +1 866 644-7811                       +1 212 584-2276
Email: shai@prolor-biotech.com             blindheim@bllbiopartners.com

SOURCE PROLOR Biotech, Inc.

Website: http://www.prolor-biotech.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement